A Study With Central Nervous System Metastatic EGFR Mutation Positive Non-small Cell Lung Cancer

A Non-interventional Survey on the EGFR (Epidermal Growth Factor Receptor) Mutation Status in Completely Resected Chinese Non-Small Cell Lung Cancer (NSCLC) Patients With Adenocarcinoma Histology

NCT01106781 ·Status: COMPLETED

A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC

NCT05223595 ·Status: UNKNOWN ·Phase: PHASE1

Early or Delayed Intervention of Brain Radiotherapy Combined With Almonertinib in EGFR Mutated NSCLC With Brain Metastases

NCT05768490 ·Status: RECRUITING ·Phase: PHASE3

Study of EGFR-TKI to Asymptomatic Brain Metastases of NSCLC

NCT02250846 ·Status: UNKNOWN ·Phase: PHASE2

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

NCT04324164 ·Status: RECRUITING

Ivonescimab Combined With Chemotherapy for the Treatment of Leptomeningeal Metastases Failed to EGFR-TKIs

NCT06766591 ·Status: NOT_YET_RECRUITING ·Phase: NA

A Retrospective Study of EGFR-TKIs,Gefitinib, Erlotinib and Osimertinib in NSCLC Patients Treatment

NCT01994057 ·Status: RECRUITING

An Observational Study of Furmonertinib for EGFR Mutation-positive NSCLC Patients With Brain Metastasis

NCT06352502 ·Status: RECRUITING

Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation

NCT04322890 ·Status: RECRUITING ·Phase: PHASE2

Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation

NCT05146219 ·Status: COMPLETED ·Phase: PHASE2

Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation

NCT04233021 ·Status: COMPLETED ·Phase: PHASE2

AI-guided Prognostication and Cranial Radiotherapy Optimization in EGFR-TKI-treated Non-small Cell Lung Cancer Patients With Baseline Brain Metastases

NCT06604689 ·Status: RECRUITING

A Prospective Observational Study Evaluating c-MET Expression and EGFR Gene Mutation Correlation With Erlotinib Response

NCT01523340 ·Status: COMPLETED

Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis

NCT04944069 ·Status: UNKNOWN ·Phase: NA

Real-World Effectiveness of Osimertinib for Patients With Non-Small Cell Lung Cancer

NCT05513664 ·Status: UNKNOWN

Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC

NCT05534113 ·Status: UNKNOWN ·Phase: PHASE2

A Study of Osimertinib-based Adaptive Treatment Guided by ctDNA EGFRm+ Monitoring in NSCLC

NCT07058519 ·Status: RECRUITING ·Phase: PHASE2

Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer

NCT04425681 ·Status: UNKNOWN ·Phase: PHASE2

EGFR-TKI Resistance Profile in Chinese Patients With Advanced EGFRm+ NSCLC

NCT02988141 ·Status: UNKNOWN

Osimertinib With Chemotherapy as First-line Therapy for EGFR Mutation-positive NSCLC

NCT06376084 ·Status: ACTIVE_NOT_RECRUITING

Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC

NCT04905550 ·Status: UNKNOWN ·Phase: PHASE2

Efficacy of Gefitinib for Brain Metastasis of Non-Small Cell Lung Cancer

NCT00614809 ·Status: UNKNOWN ·Phase: PHASE2

Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer

NCT05284539 ·Status: RECRUITING ·Phase: PHASE2

Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC

NCT05009836 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3

Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer

NCT05104281 ·Status: UNKNOWN ·Phase: PHASE3